<table border="0" cellpadding="0" cellspacing="0" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td>
<content stylecode="bold">Table 6: Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes<sup>*</sup>
</content>
<br/>
</td>
</tr>
<tr>
<td>Clarithromycin Pretreatment Results<br/>
</td>
<td>Clarithromycin Post-treatment Results<br/>
</td>
</tr>
<tr>
<td>  <br/>
</td>
<td>
<content stylecode="italics">H. pylori</content>
<br/>negative – eradicated<br/>
</td>
<td>
<content stylecode="italics">H. pylori</content> positive – not<br/>eradicated<br/>Post-treatment susceptibility results<br/>
</td>
</tr>
<tr>
<td>S<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>I<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>R<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>No MIC<br/>
</td>
</tr>
<tr>
<td>Triple Therapy 14-Day (lansoprazole 30 mg twice daily /amoxicillin 1 gtwice <br/>daily/clarithromycin 500 mg twice daily)(M95-399, M93-131, M95-392)<br/>
</td>
</tr>
<tr>
<td>Susceptible<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>112<br/>
</td>
<td>105<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>7<br/>
</td>
</tr>
<tr>
<td>Intermediate<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>3<br/>
</td>
<td>3<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
</tr>
<tr>
<td>Resistant<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>17<br/>
</td>
<td>6<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>7<br/>
</td>
<td>4<br/>
</td>
</tr>
<tr>
<td>Triple Therapy 10-Day (lansoprazole 30 mg twice daily /amoxicillin 1 g twice <br/>daily/clarithromycin 500 mg twice daily) (M95-399)<br/>
</td>
</tr>
<tr>
<td>Susceptible<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>42<br/>
</td>
<td>40<br/>
</td>
<td>1<br/>
</td>
<td>
<content stylecode="bold">  </content>
<br/>
</td>
<td>
<content stylecode="bold">  </content>
<br/>
</td>
<td>1<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
</tr>
<tr>
<td>Intermediate<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>
<content stylecode="bold">  </content>
<br/>
</td>
<td>
<content stylecode="bold">  </content>
<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
</tr>
<tr>
<td>Resistant<content stylecode="bold">
<sup>†</sup>
</content>
<br/>
</td>
<td>4<br/>
</td>
<td> 1<br/>
</td>
<td>  <br/>
</td>
<td>
<content stylecode="bold">  </content>
<br/>
</td>
<td>
<content stylecode="bold">  </content>
<br/>
</td>
<td>3<br/>
</td>
<td>  <br/>
</td>
<td>  <br/>
</td>
</tr>
<tr>
<td>
<content stylecode="bold">*</content>Includes only patients with pretreatment clarithromycin susceptibility test results <br/>
<content stylecode="bold">†</content>Susceptible (S) MIC ≤0.25 mcg/mL, Intermediate (I) MIC 0.5 - 1.0 mcg/mL, <br/>Resistant (R) MIC ≥2 mcg/mL<br/>
</td>
</tr>
</tbody>
</table>